HIFU-CCL19/21 Axis Enhances Dendritic Cell Vaccine Efficacy in the Tumor Microenvironment
Pharmaceutics · 06.01.2025 · 17 (1) · 65
DOI: 10.3390/pharmaceutics17010065 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 06.01.2025. Verfasst von Bum-Seo Baek und 4 weiteren Autor:innen. Beteiligte Einrichtung: Wide River Institute of Immunology, Seoul National University College of Medicine, Hongcheon 25159, Gangwon, Republic of Korea. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and ICT, Ministry of Health and Welfare, Ministry of Science, ICT and Future Planning.
Abstract (Originalsprache)
Background/Objectives: Effectively targeting treatment-resistant tumor cells, particularly cancer stem cells (CSCs) involved in tumor recurrence, remains a major challenge in immunotherapy. This study examines the potential of combining mechanical high-intensity focused ultrasound (M-HIFU) with dendritic cell (DC) vaccines to enhance immune responses against OLFM4-expressing tumors, a CSC marker linked to immune evasion and tumor growth.
Methods
M-HIFU was applied to induce immunogenic cell death by mechanically disrupting tumor cells, releasing tumor-associated antigens and creating an immunostimulatory environment. DC vaccines loaded with OLFM4 were then administered to boost the immune response within this primed environment.
Results
The combination of M-HIFU and DC vaccine significantly inhibited tumor growth and metastasis, with enhanced T-cell activation and increased recruitment of immune cells due to elevated chemokines CCL19 and CCL21. This synergy promoted immune memory, reducing the likelihood of recurrence.
Conclusions
M-HIFU effectively promotes the migration of DC vaccines through CCL19/21, presenting a promising approach for cancer treatment. Further studies are recommended to optimize this combination for clinical applications, with potential to improve patient outcomes in challenging cancer types.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Wide River Institute of Immunology, Seoul National University College of Medicine, Hongcheon 25159, Gangwon, Republic of Korea.
- Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
- Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
- Shaperon Inc., Ltd., Seoul 06373, Republic of Korea.
ORCID-Profile: Bum-Seo Baek, Seung-Yong Seong
Förderung
- Ministry of Science and ICT
- Ministry of Health and Welfare
- Ministry of Science, ICT and Future Planning
Zitieren
APA
Baek, B. S., Park, H., Choi, J. W., Lee, E. Y., & Seong, S. Y. (2025). HIFU-CCL19/21 Axis Enhances Dendritic Cell Vaccine Efficacy in the Tumor Microenvironment. Pharmaceutics, 17(1), 65. https://doi.org/10.3390/pharmaceutics17010065
Vancouver
Baek BS, Park H, Choi JW, Lee EY, Seong SY. HIFU-CCL19/21 Axis Enhances Dendritic Cell Vaccine Efficacy in the Tumor Microenvironment. Pharmaceutics. 2025;17(1):65. doi:10.3390/pharmaceutics17010065
BibTeX
@article{Baek2025,
author = {Baek, Bum-Seo and Park, Hyunmi and Choi, Ji-Woong and Lee, Eun-Young and Seong, Seung-Yong},
title = {HIFU-CCL19/21 Axis Enhances Dendritic Cell Vaccine Efficacy in the Tumor Microenvironment},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {1},
pages = {65},
doi = {10.3390/pharmaceutics17010065}
}
EUVIMED